生命科学资讯

FDA issues safety alert on Trividia blood glucose monitors

Generate plans $425M IPO to bankroll antibody's phase 3 asthma trials

Gossamer's stock sinks after phase 3 pulmonary arterial hypertension fail

Frontier, Harbour do licensing deals with GSK, Solstice

A federal experiment opens up a new market for digital health — if it works

Vanda gets FDA nod for atypical antipsychotic Bysanti

Biggest gainers and losers for Feb. 16-20, 2026

Roche to stop work on bone health treatment for Duchenne

Merck reorganizes; Blackstone to fund trials for J&J drug

First test of gene therapy for rare form of autism is underway

Merck to split cancer, specialty drug businesses in leadership shakeup

How does the FDA really feel about psychedelics? We could soon find out.

Brise Pharmaceutical synthesizes new TRPM3 antagonists

Bioversys tuberculosis combo targets drug resistance

Gilead to buy Arcellx in $7.8B wager on multiple myeloma cell therapy

MoonLake's phase 2 arthritis win kicks off pivotal year for IL-17 nanobody

Gilead to acquire cell therapy partner Arcellx for $7.8B

Microfluidics Research Report 2026-2035: A $20.73 Billion - GlobeNewswire

Microfluidics Research Report 2026-2035: A $20.73 Billion Market by 2030 with Thermo Fisher Scientific, PerkinElmer, Dolomite, Agilent Technologies, Bio-Rad Laboratories, and Fluidigm Leading - Yahoo Finance

Novo Nordisk’s CagriSema beaten by Lilly’s Zepbound in head-to-head obesity trial